Last updated on August 2018

Do you have high-risk, localized or locally advanced prostate cancer that requires radiation therapy?


Brief description of study

Do you have high-risk, localized or locally advanced prostate cancer that requires radiation therapy?

Detailed Study Description

The ATLAS clinical research study is being conducted to assess the safety and efficacy of an investigational medication plus gonadotropin releasing hormone agonist (GnRHa) in subjects with high-risk, localized or locally advanced prostate cancer receiving treatment with primary radiation therapy.

The study will enroll 1,500 patients with high-risk, localized or locally advanced prostate cancer receiving treatment with primary radiation therapy. For most study patients, this study will last for 6-9 years. At the start of the treatment, you will be randomly assigned to one of two groups. You may receive the investigational drug or a placebo.

This clinical research study will assess metastasis free survival in addition to safety and efficacy.

Clinical Study Identifier: TX142556

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.